LDLR and familial hypercholesterolemia: The first one aims at controlling circulating PCSK9 levels and/or its interaction with liver LDL receptors to reduce blood cholesterol and to prevent the hypercholesterolemia-induced BBB damage and the consequent alterations in the brain lipid contents.